Stereotaxis (STXS) Q2 2026 Earnings Call Transcript
Stereotaxis (STXS) reported Q2 2026 revenue of $7.7M, down from $8.8M YoY due to no robotic system delivery. Robotic catheter revenue grew 270% sequentially to $1M. Recurring revenue increased to $6.2M. Gross margin was 58%. The company expects cash flow profitability by H1 2027 and guided Q3/Q4 recurring revenue at $7M and $8M, respectively. Management highlighted supply constraints and transition risks.
How this was made
The 30-second read
Why it matters
The call centers on Q2 results and forward guidance, with management emphasizing supply constraints limiting robotic system deliveries and backlog conversion, while recurring revenue grows on MAGiC adoption. It also reiterates a profitability timeline (cash-flow profitability in 1H 2027) tied to catheter ramp and manufacturing output increases.
Market read
Traders will likely focus on whether the company can convert backlog into deliveries given stated manufacturing bottlenecks, and whether guided recurring revenue and systems installation plans are achievable into 3Q and 4Q 2026.
What to watch
The guidance depends on installations (GenesisX, Synchrony) and hospital standardization decisions, which could slip if compatibility efforts with X-ray manufacturers take longer than expected.
Background
Stereotaxis is transitioning from a legacy model toward a proprietary robotic ecosystem (MAGiC catheter, GenesisX robot, Synchrony digital surgery system) and recently closed the Robocath acquisition (July 2026).
Ticker impact
Stereotaxis reported Q2 2026 revenue of $7.7M, guided recurring revenue to $7M in Q3 and $8M in Q4, and flagged supply constraints from contract manufacturer Osypka.
Moderate upside bias if investors believe Osypka output can expand fast enough to sustain the guided recurring revenue and systems installation cadence; downside risk if supply remains the binding constraint.
The call provides multiple forward-looking datapoints (recurring and systems guidance, cash-flow profitability timing, and explicit supply-constrained backlog) that can reprice expectations, but it is still an earnings-call transcript rather than a fresh filing or surprise datapoint.
Market effects
Highlights a medtech commercialization model shift toward proprietary consumables and recurring revenue, with manufacturing capacity as the key gating factor.
Primarily US adoption narrative (12 MAGiC sites, GenesisX purchase by an academic medical center), which can influence US medtech sentiment.
Mentions global patient treatment volume (>150,000) but the actionable near-term catalysts are US supply and installation schedules.
Counterpoint
Even with improving adoption, the systems revenue decline and negative free cash flow suggest the business may remain dependent on continued manufacturing scale-up before profitability becomes credible.
Key entities
- companyStereotaxis, Inc.
Reported Q2 2026 financials and provided Q3/Q4 recurring and systems revenue guidance, while citing supply constraints from contract manufacturing.
- contract_manufacturerOsypka
Contract manufacturer cited as the source of supply constraints limiting catheter/robotic system output.
- acquisition_targetRobocath
Endovascular robotics company acquired by Stereotaxis in July 2026 to expand into multi-specialty navigation.
- productMAGiC
Proprietary robotic catheter launched in the US, driving recurring catheter revenue growth and adoption at 12 US sites.
- productGenesisX
Robotic magnetic navigation system; management expects installations and compatibility steps to broaden adoption.
